Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the optimal length of continuation treatment with fluoxetine for children and adolescents with major depressive disorder, as well as the factors that may contribute to positive response during acute and continuation treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Fluoxetine

Criteria

Inclusion Criteria:

• Currently being treated on an outpatient basis

• Currently attending school

• Diagnosis of non-psychotic major depressive disorder (MDD)

• Duration of illness is at least 4 weeks

• In good general medical health

• Normal intelligence

Exclusion Criteria:

• Lifetime history of any psychotic disorder, including psychotic depression

• Diagnosis of bipolar I or II disorder

• History of alcohol or substance abuse or dependence within 6 months of study entry

• Lifetime history of anorexia nervosa or bulimia

• Pregnant or breastfeeding

• Does not agree to use an effective form of contraception (i.e., IUD, birth control pills, or barrier devices)

• Any chronic medical illness requiring regular medication

• Currently taking medication with psychotropic effects (i.e., anticonvulsants, steroids, etc.), other than stable stimulant treatment

• A first degree relative has bipolar I disorder

• Previous adequate treatment with fluoxetine was ineffective (defined as at least 20 mg/day for 4 weeks)